Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / PHAT - Phathom Pharmaceuticals announces revenue interest financing agreement for up to $260M

PHAT - Phathom Pharmaceuticals announces revenue interest financing agreement for up to $260M

Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals (NASDAQ:PHAT) announces a revenue interest financing of up to $260M in non-dilutive capital. The agreement provides for an upfront $100M cash payment and an additional $160M cash payment upon FDA approval of vonoprazan for treatment of EE. Sagard Healthcare Partners, NovaQuest Capital Management and Hercules Capital have committed to providing $260M, including the first $100M payment and commitments for an additional $160M upon EE approval.

For further details see:

Phathom Pharmaceuticals announces revenue interest financing agreement for up to $260M
Stock Information
Company Name: Phathom Pharmaceuticals Inc.
Stock Symbol: PHAT
Market: NYSE
Website: phathompharma.com
Menu
PHAT PHAT Quote PHAT Short PHAT News PHAT Articles PHAT Message Board
Get PHAT Alerts

News, Short Squeeze, Breakout and More Instantly...